Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

@article{Venkatraman2006DiscoveryO,
  title={Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:},
  author={Srikanth Venkatraman and St{\'e}phane L. Bogen and Ashok Arasappan and Frank Bennett and Kevin Chen and Edwin Jao and Yi-Tsung Liu and Raymond G. Lovey and Siska Hendrata and Yuhua Huang and Weidong Pan and Tejal N Parekh and P. De Pinto and Veljko Popov and Russel E Pike and Sumei Ruan and Bama Santhanam and Bancha Vibulbhan and Weiwei Wu and Weiying Yang and Jianshe Kong and Xiang Liang and Jesse C S Wong and R Liu and Nancy Butkiewicz and Robert Chase and Andrea Hart and Sony Agrawal and Paul Ingravallo and John S Pichardo and Rong Kong and B. M. Baroudy and Bruce Malcolm and Zhuyan Guo and Andrew J. Prongay and Vincent Madison and Lisa Broske and Xiaoming Cui and Kuo-Chi Cheng and Yunsheng Hsieh and J M Brisson and Danial Prelusky and Walter A. Korfmacher and Ronald F White and Susan Bogdanowich-Knipp and Anastasia Pavlovsky and Prudence Bradley and Anil K. Saksena and Ashit K. Ganguly and John J. Piwinski and Viyyoor M. Girijavallabhan and F. George Njoroge},
  journal={Journal of medicinal chemistry},
  year={2006},
  volume={49 20},
  pages={6074-86}
}
Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-alpha or polyethylene glycol (PEG)-interferon-alpha alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…